Company profilePharmaceutical#512 of 1,318 in Pakistan2 DRAP alerts

Aspin Pharma DML: 000045

Pharmaceutical company · 26 brands · 52 molecules

Ranked #35 of 62 companies in Antivirals For Systemic Use

26 registered products 16 pharmaceutical brands 52 distinct molecules 2 DRAP alerts

Company overview

26
registered products
16
pharmaceutical brands
52
distinct molecules
7
therapeutic classes
2
DRAP alerts

Aspin Pharma DML: 000045 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 26 product registrations across 52 distinct molecules. Its portfolio is concentrated in Antivirals For Systemic Use and Other Beta-Lactam, Cephalosporins & Penems. DRAP has issued 2 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Aspin

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

1
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20261

Top molecules by brand count

Ondansetron2 brands
Miconazole2 brands
Cilastatin1 brand
Imipenem1 brand
Imipemide1 brand
Rivaroxaban ...... 20 Mg1 brand
Rivaroxaban ...... 2.5 Mg1 brand
Rivaroxaban ...... 10 Mg1 brand

Therapeutic classes

Antivirals For Systemic Use · 2Other Beta-Lactam, Cephalosporins & Penems · 1Beta-Lactam Antibacterials, Penicillins · 1Anti-Infectives · 1Anthelmintic · 1Antiemetics & Antinauseants · 1Gynaecological Anti-Infective & Antiseptics · 1

Conditions treated

Worms/Scabies/Amoebiasis · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official29 products · Rs 56.78 – Rs 35,110.84
DVAGO6 products · Rs 95 – Rs 486
Servaid3 products · Rs 63.58 – Rs 357.84
Median across source: Rs 357.6

Regulatory record

2 alerts in the DRAP feed we track.

Strategic Plan 2026-2030
2026-05-06
Risk Communication and Awareness Plan of Pharmacovigilance Activities (Edition 01)
2026-03-11

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Atco Pharma International (Pvt) Ltd holds 231 molecules not in this portfolio
Acetylsalicylic AcidAcyclovirAdapaleneAdapleneAlbuterolAminophylline
NABIQASIM INDUSTRIES (PVT) LTD. holds 195 molecules not in this portfolio
2 MiuAcefyllin PiperazineAcefyllineAcetaminophinAcetylsalicyclic AcidAcyclovir
BIO LABS (PVT) LTD. holds 139 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate

Get the full profile for Aspin

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.